Articles
Cracking RAS: It took over 30 years to hit this ubiquitous oncogene – was it worth the wait?
RAS oncogenes and their proteins have central roles in almost all cancers, including leukaemias, multiple myelomas, skin cancers and many solid tumours, making the RAS protein family an ideal cancer target. But efforts to develop clinically efficacious drugs to target…
The CRISPR revolution: it’s transforming cancer research, can it do the same for treatment?
CRISPR is a revolutionary gene-editing tool that allows scientists to cut DNA with extraordinary precision and make changes to the genome. The technology was a gift to cancer researchers, whose efforts to understand the roles played by different genes rely…
New options to protect long-term health of children treated for cancer
Childhood cancer is considered a success story of modern medicine, with more than 90% of children now surviving long-term in high-income countries, up from just 10% 65 years ago. Yet many children who survive their cancer go on to experience…
AI-generated radiotherapy planning could boost access to high-quality treatment across the globe
Can artificial intelligence help design radiotherapy treatment plans, reducing time and cost while matching the quality of skilled professionals? That is the question that a new multi-centre and multi-arm ARCHERY study is trying to answer. The global study, still at…
Precision cancer nursing: using the personalised medicine paradigm to improve patient care
Precision medicine is transforming the way we treat cancer. Oncology is evolving from treating purely on the basis of a broad indication to a tailored approach that is based on a tumour’s molecular characteristics, and usually requires complex combinations of…
CAR T cells v chemo for childhood leukaemia: are we ready for the next step?
Chimeric antigen receptor (CAR) T cells, genetically engineered immune cells targeted to attack cancers, are one of the most exciting breakthrough cancer treatments in oncology today. After decades of incremental development, its clinical efficacy was shown in 2010, with the…
How do I respond? Advice for friends and family on supporting someone through cancer
A few days after being diagnosed with cancer, at only 32 years of age, Katarzyna Chmielewska-Wojciechowska met a friend who asked, in passing, how she was doing. She told him. His response was to sympathise and offer reassurance. He knew…
Molecular tumour boards: translating data into tailored therapeutics
Developments in molecular diagnostics are allowing us to capture an extraordinarily detailed picture of the genomic and other molecular changes that characterise a given tumour specimen. But making best use of the information at our disposal is proving quite a…
Unpaid women carers: recognising their contribution and their needs in Latin America
Researchers and public policies have historically overlooked the challenges of informal caregiving for cancer patients in Latin America. Now, public health experts are working to profile this neglected group, evaluate their quality of life and put an economic value on…
‘Fragile’ cancer patients hit by Turkish earthquake need urgent support
Hakan Büyükhatipoğlu was at home with his family in Gaziantep at 4.17 in the morning of 6th February when the earthquake struck. The epicentre of that first quake was less than 40 km from the city. Less than 12 hours…